Compare BAX & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAX | ALGN |
|---|---|---|
| Founded | 1931 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 10.2B |
| IPO Year | N/A | N/A |
| Metric | BAX | ALGN |
|---|---|---|
| Price | $18.60 | $157.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 13 |
| Target Price | $25.67 | ★ $190.50 |
| AVG Volume (30 Days) | ★ 8.3M | 1.6M |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.16 |
| Revenue | ★ $11,023,000,000.00 | $3,982,622,000.00 |
| Revenue This Year | $5.20 | $2.58 |
| Revenue Next Year | $2.02 | $3.41 |
| P/E Ratio | ★ N/A | $30.45 |
| Revenue Growth | ★ 3.90 | 0.56 |
| 52 Week Low | $17.40 | $122.00 |
| 52 Week High | $37.74 | $246.19 |
| Indicator | BAX | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.20 | 73.38 |
| Support Level | $18.33 | $144.00 |
| Resistance Level | $19.17 | $152.99 |
| Average True Range (ATR) | 0.54 | 4.97 |
| MACD | 0.21 | 1.74 |
| Stochastic Oscillator | 63.23 | 92.40 |
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.